Early risk stratification has the potential to play an important role in ST-elevation myocardial
infarction (STEMI) 1 patients who are to be treated with primary percutaneous coronary …

Multiple biomarkers improve prognostication for long-term mortality in ST-segment elevation
myocardial infarction (STEMI). However, one-third of mortality after STEMI occurs within …

Objectives: We investigated whether multiple biomarkers improve prognostication in ST-
segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous …

Introduction: Myocardial infarction with ST-segment elevation (STEMI) is the coronary artery
disease associated with the highest risk of morbimortality; however, this risk is …

Despite significant advances in the treatment of ST elevation myocardial infarction (STEMI),
there remains a significant short-term and long-term increased mortality risk. Risk …

Background Differences in biomarkers reflective of pathobiology and prognosis between ST-
elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction …

In recent years, much effort has been devoted to risk stratification of patients with acute
coronary syndromes (ACS), mainly focusing on patients with non–ST-segment elevation …

Early prediction of significant morbidity or mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) represents an unmet clinical need. In phenotypically …

Background The incremental prognostic value of admission measurements of biomarkers
beyond clinical characteristics and extent of coronary artery disease (CAD) in patients …

INTRODUCTION: We assessed the long-term prognostic value of an easy-to-do multiple
cardiac biomarkers score after a revascularized acute myocardial infarction (MI) in order to …